Morphic Medical Inc.
16
1
1
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
25.0%
4 terminated/withdrawn out of 16 trials
71.4%
-15.1% vs industry average
0%
0 trials in Phase 3/4
100%
10 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
RESET System Pivotal Trial (Rev F)
Role: lead
EndoBarrier Register Deutschland-Safety and Efficacy of the Endoscopic Duodenal-Jejunal Bypass Sleeve
Role: collaborator
Study for Pre-Surgical Weight Loss in Type II Diabetes Patients
Role: lead
A Multicenter Study for Pre-Surgical Weight Loss
Role: lead
Post Marketing Study in Subjects Who Have Type 2 Diabetes Using the EndoBarrier™ Gastrointestinal Liner
Role: lead
Registry Observing EndoBarrier® Treatment Outcomes in Subjects With Type 2 Diabetes and/or Obesity
Role: lead
Study of EndoBarrier Liner for Treatment of Type 2 Diabetes Study
Role: lead
Multi-Center Pre-Bariatric Weight Loss Study
Role: lead
Study of Obese Subjects Previously Implanted With the EndoBarrier Gastrointestinal Liner
Role: lead
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
Role: lead
A Study of the GI Sleeve for the Treatment of Type 2 Diabetes
Role: lead
Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity
Role: lead
Study for Short Term Weight Loss in Candidates for Bariatric Surgery
Role: lead
An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System
Role: lead
EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects
Role: lead
A Pilot Trial of the EndoBarrier™ Flow Restrictor for Glycemic Improvement in Type 2 Diabetics
Role: lead
All 16 trials loaded